MT133

MT133 is an early-stage biopharmaceutical candidate being developed by Medytox (also referred to as Miotox in some contexts) for the treatment of various cancers. As of early 2024, the drug is in the preclinical or discovery phase of development. It is part of Medytox's strategic expansion into the oncology therapeutic area, leveraging their expertise in biopharmaceutical development to diversify beyond their core botulinum toxin business. While specific details regarding its molecular target, therapeutic modality (such as monoclonal antibody or recombinant protein), or specific cancer indications have not been publicly disclosed in detail, it is listed as a key oncology asset in the company's early-stage pipeline.